Forget NuScale: This Nuclear Energy Stock Is the Smarter Bet Right Now

NuScale's shares have retreated to about $10 from a $53.43 peak after the company canceled its Idaho project, delayed Romania deployments to 2033, and faces an expected 21% 2026 revenue decline to $25 million alongside a $181 million net loss. The article favors BWX Technologies, citing its $7.3 billion backlog, 50% year-over-year increase, and projected 2025-2028 revenue and EPS CAGRs of 12% and 16%, respectively. BWX's defense-oriented nuclear supply-chain position, acquisitions, and existing profitability are presented as lower-risk exposure to nuclear growth than NuScale's 169x sales valuation.

Analysis

The relevant dispersion is not simply profitable incumbent versus pre-revenue developer: BWXT is levered to constrained nuclear-qualified manufacturing capacity, where Navy demand and fuel-processing qualifications can tighten capacity before commercial SMR orders convert. That creates a plausible 6-18 month mix/timing benefit through backlog conversion and pricing, while SMR's equity value remains dependent on external project financing, customer commitments, and a long-dated deployment schedule. FLR's full exit removes a potentially informed strategic holder and makes future SMR project wins harder to interpret absent third-party EPC and financing support.

BWXT's principal risk is that its defense-heavy valuation already capitalizes a sizable share of expected growth; acquisition integration and working-capital demands could prevent EPS growth from translating into free cash flow. The nearer-term catalyst path is Navy procurement visibility, Kinectrics/Precision Components margin realization, and any incremental HALEU/TRISO capacity award over the next 1-3 quarters. Falsification for a BWXT long is a backlog-to-revenue conversion slowdown, segment-margin dilution, or FY27 EPS guidance that fails to support mid-teens growth.

Consensus may be underestimating the option value of SMR's intellectual property and regulatory position if a sovereign-backed Romanian financing package or hyperscaler power purchase agreement emerges, but the stock needs a funded contract rather than another memorandum to rerate sustainably. At its current revenue base, even modest cost overruns or another schedule revision materially extend dilution risk; a sharp short can be dangerous because nuclear-policy headlines and strategic capital can drive violent squeezes.

Key Decisions for Investors

• Initiate a 6-12 month long BWXT / short SMR pair, sized beta-neutral: BWXT captures near-term qualified-capacity and defense cash flows while SMR bears project-finance and dilution risk. Target 15-20% relative outperformance; stop/reassess if SMR announces a fully financed, binding commercial order with credible EPC participation.
• For long-only exposure, accumulate BWXT only on post-earnings weakness if management reiterates backlog conversion and FY27 EPS growth; use a 10-12% downside discipline, as multiple compression is the primary risk rather than a demand collapse.
• Maintain SMR as an event-driven watch, not a core short, until cash runway, quarterly operating burn, and contract funding sources are updated. A financed Romanian project, hyperscaler PPA, or DOE-backed award would invalidate the base bear case and could justify call-spread hedges against the pair short.
• Avoid treating BW as a substitute for BWXT: any nuclear upside is indirect, while its legacy operating exposure produces materially different margin and balance-sheet sensitivity.